Cell Applications, Inc. Launches Human Dendritic Cells and Media
SAN DIEGO, Aug 26, 2016 -- Today CAI introduced Human Dendritic Cells to their primary Blood Cell portfolio. Isolated from peripheral blood, the cells (HDC-PB for short) arise from a distinct hematopoietic lineage and help regulate the immune system. They mount adaptive immune responses to foreign antigens, prime T cells through antigen presentation and can induce tolerance to self-antigens. Academic & industrial research is driving toward new therapeutic approaches to modulate dendritic cells for vaccines and therapies to suppress pathogens, tumors and autoimmune disorders. Dendritic Cells complement and extend CAI's other blood-derived cells, like T & B Lymphocytes, Hematopoietic Stem Cells, Mononuclear Cells, Monocytes, Macrophages and Microglial Cells. Immunologists and others who study blood disorders can now source most blood cell types and media from one place. In addition to simplifying orders, lab workers can also benefit from the consistency of single-source products. The uniformity can improve the soundness of data comparing multiple cell types, for instance. Currently undergoing an expansion phase, Cell Applications plans additional new primary cell products and services over the remainder of the year and into early 2017.
Press & Media Relations